CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today announced it has been named among the 100 Best Companies to Work For in the United States by FORTUNE. This is the first year that Millennium, a wholly owned subsidiary of Japan’s largest pharmaceutical company Takeda Pharmaceuticals, has been included in this list. Millennium was the highest ranked newcomer on this year’s list.
“Being named among the top 100 employers in the country is a tremendous accomplishment for our company, and a true reflection of the passion, commitment and pride that our employees have for their work,” said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. “This recognition from FORTUNE is a result of our Company’s commitment to patients, our community and our own employees.”
Over the past year, Millennium has also been named a top employer by the Boston Globe, the Boston Business Journal, Science magazine, The Scientist and the Dave Thomas Foundation.
To pick the 100 Best Companies to Work For, FORTUNE partners with the Great Place to Work Institute to conduct the most extensive employee survey in corporate America. Three hundred eleven companies participated in this year's survey. Two-thirds of a company's score is based on the results of the Institute's Trust Index survey, which is sent to a random sample of employees from each company. The survey asks questions related to their attitudes about management's credibility, job satisfaction, and camaraderie. The other third of the scoring is based on the company's responses to the Institute's Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions about hiring practices, internal communications, training, recognition programs and diversity efforts. Any company that is at least seven years old with more than 1,000 U.S. employees is eligible.
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com/media
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Genetics Hospitals Oncology Pharmaceutical Other Health Professional Services Human Resources Research FDA Science